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Journal of Cystic Fibrosis 13 (2014) S1–S2EditorialStandards of Care for Cystic Fibrosis ten years laterIn 2004 the European Cystic Fibrosis Society (ECFS)
convened a Consensus Conference on standards of care for
cystic fibrosis (CF). CF professionals from many European
countries, and some from outside Europe, produced a document
that was later published in the Journal of Cystic Fibrosis [1].
This consensus on standards of care proved to be very useful
for CF centres negotiating with the funding agencies in their
countries and set the scene for better CF care in Europe.
Ten years later CF care worldwide and specifically in
Europe has evolved in many ways:
- Early diagnosis through neonatal screening has proliferated
across Europe [2].
- The adult population of patients has been steadily increasing
and in some countries has now numerically passed the
paediatric population [3].
- New treatments are available, including mutation-specific
therapies that might have the potential to change the natural
history of the disease [4].
- More emphasis is given to clinical research and a network of
European CF centres has been established with the aim of
facilitating high quality clinical trials to translate new
therapies into clinical care [5].
- Epidemiological data from many European countries have
become available through the EuroCareCF project [6] and
national and international registries [3]. Evidence of disparities
in allocation of resources and in clinical outcomes has
emerged.
These momentous changes prompted the ECFS to plan an
updated version of the 2004 document. A broad spectrum of CF
professionals from Europe, North America and Australia and
various representatives of patient support groups were involved
in pre-meeting consultations and in the drafting of preliminary
documents. These were discussed during a dedicated Consensus
Conference that took place in Verona, Italy, on April 12–13,
2013, attended by 39 experts and stakeholders. The three articles
in this supplementary issue of the Journal of Cystic Fibrosis are
the results of this process.
Each one of the three papers has been developed by a team
of professionals/experts directed by a group coordinator and
addresses a specific field of the standards of care. These threehttp://dx.doi.org/10.1016/j.jcf.2014.03.008
1569-1993/© 2014 European Cystic Fibrosis Society. Published by Elsevier B.V. Oareas cover: a) the required framework of the CF Centre; b) best
clinical practice; and c) quality management in CF care.
The Centre Framework document emphasizes the unques-
tionable role of dedicated CF centres for achieving optimal
outcomes. The paper highlights the importance of the multidis-
ciplinary team, describes the general structure of paediatric and
adult CF centres and stresses the need for their cooperation and
for a transition programme. The roles of professionals involved in
the care of CF are described, including the clinical director,
specialist doctors, specialist nurses, physiotherapists, dietitians,
microbiologists, pharmacologists, psychologists, clinical geneti-
cists and social workers. All disciplines are strongly encouraged
to be members of their national and international specialist
groups, to update themselves by attending meetings, and to
participate in audit and research whenever possible. The
challenges related to the development of dedicated health
services in low income countries and the perspectives of people
with CF mediated by patients' organisations are also discussed.
The Best Practice document describes the services centres
should provide using a question and answer model. The paper
is extensive, and difficult to condense in a few sentences. A
synopsis of the main messages includes:- Early and accurate detection through neonatal screening and
expertise to undertake biochemical and genetic diagnostic
testing are vital and enable access to specialist care from
early in life.
- Prompt recognition of pulmonary infection and deterioration
permits intervention with timely treatments which are
proven to reduce the impact of CF on the lungs.
- Nutritional and metabolic complications require regular
monitoring and timely and effective intervention.
- CF professionals need to have experience and expertise in
all common complications and to have developed referral
pathways with other disciplines to support more complex
situations.
- Appropriate management and communication are particu-
larly important at transplantation referral and end of life.
- Despite excellent improvement in clinical outcomes
and survival for people with CF, psychological complica-
tions are common for the patient and their family and
require early recognition, assessment and management withpen access under CC BY-NC-ND license.
S2 Editorialthe active involvement of experienced psychological health
care professions.
In consideration of the magnitude of the topics, specific
treatments and procedures are not described in detail. For
example, the necessity of having protocols for Pseudomonas
aeruginosa eradication is clearly expressed, but single proto-
cols are not discussed.
The Quality Management document reviews management of
quality of care for individuals with CF at several levels: patient,
centre, regional, national and international. Improvement issues
are examined with particular reference to annual assessment,
patient quality management charts, CF team sessions, therapy
goals, certification, peer review, public reporting, quality groups,
ranking, learning from best practice, interaction with registries,
benchmarking, and cooperation with national organisations.
A lesson learned after the publication of the previous
standards of care document [1] was that although awareness of
it and its dissemination in Europe were good, its implementation
was quite dishomogeneous [7,8]. The heterogeneity of care
organisations in Europe and the absence in some countries of
dedicated CF centres plus inadequate resources made it difficult,
if not impossible, to universally apply the suggested standards.
The authors of the present documents are aware of the
barriers that some countries, in which CF services are absent or
minimal, may encounter in implementing the new standards of
care. Their accomplishment is made challenging by deficien-
cies in political prioritization, inappropriate funding and a lack
of staff recruitment and training. However, we strongly believe
that all European nations should strive to achieve a model of CF
care in accordance with the ECFS recommendations. Inequal-
ities in levels of assistance and the extreme variation in the
survival of people with CF across European countries [6] are
not acceptable, and every effort must be made to deliver high
standards. Optimal care may not be an easily achievable target
and in some less advantaged countries a stepwise approach may
be the only deliverable approach, but the present standards
should remain as a goal.
ECFS considers the publication of these documents as an
important step in the provision of the best possible care to people
with CF, and plans to make it not a one-off action, but a
component of a wider project which will include further
initiatives. The concepts in the articles will be integrated in the
papers produced by the Joint Task Force on CF Adult Care
assembled by the European Respiratory Society and the ECFS.
Additional developments under consideration are the periodical
review and update of the Best Practice section, the production of
training tools for quality improvement and the analysis of potential
international quality indicators in collaboration with the ECFS
Registry.
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